Codexis amd Arch Pharmalabs achieve development milestone
Codexis, Inc. announced it has achieved an important development milestone under a research and manufacturing agreement with Arch Pharmalabs, Ltd. Arch has successfully integrated Codexis' ThoroughBred(TM) biological catalysts and proprietary biocatalytic system into commercial production of a key intermediate used in the manufacture of a high-value pharmaceutical active pharmaceutical ingredient (API). Arch will continue to scale-up the manufacturing process and provide commercial quantities of the intermediate.
Under terms of the agreement announced in October 2005, achievement of the milestone triggers an undisclosed payment to Codexis. Further terms were not announced.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.